Valproate-Associated Transaminitis and Rhabdomyolysis
- PMID: 37261170
- PMCID: PMC10229196
- DOI: 10.7759/cureus.38348
Valproate-Associated Transaminitis and Rhabdomyolysis
Abstract
Valproic acid (VPA), a common anti-epileptic with prevalent use, has many side effects such as alopecia, abdominal discomfort, thrombocytopenia, etc. Other than those documented, publications cite the drug's rare side effects, such as hepatotoxicity, coagulation disorders, hyperammonemic encephalopathy, rhabdomyolysis, etc. We present the case of a 24-year-old man who was started on valproic acid after a seizure episode and developed mild transaminitis and rhabdomyolysis within 24 hours of drug initiation. Cessation of the drug led to the resolution of raised creatinine kinase and transaminase levels.
Keywords: acute hepatotoxicity; non-traumatic rhabdomyolysis; rare side effect; rhabdomyolysis; seizure medications; transaminitis; valproic acid; valproic acid toxicity.
Copyright © 2023, Sharma et al.
Conflict of interest statement
The authors have declared that no competing interests exist.
References
-
- Valproate-associated hepatotoxicity and its biochemical mechanisms. Eadie MJ, Hooper WD, Dickinson RG. https://doi.org/10.1007/BF03259935. Med Toxicol Adverse Drug Exp. 1988;3:85–106. - PubMed
-
- Valproic acid-induced hepatotoxicity in Alpers syndrome is associated with mitochondrial permeability transition pore opening-dependent apoptotic sensitivity in an induced pluripotent stem cell model. Li S, Guo J, Ying Z, et al. Hepatology. 2015;61:1730–1739. - PubMed
-
- Pathogenesis of renal failure in rhabdomyolysis: the role of myoglobin. Holt S, Moore K. Exp Nephrol. 2000;8:72–76. - PubMed
Publication types
LinkOut - more resources
Full Text Sources